World Library  
Flag as Inappropriate
Email this Article


Article Id: WHEBN0001289702
Reproduction Date:

Title: Nizatidine  
Author: World Heritage Encyclopedia
Language: English
Subject: Ranitidine, Famotidine, Betazole, Histamine receptor, Antihistamine
Publisher: World Heritage Encyclopedia


Systematic (IUPAC) name
Clinical data
Trade names Axid
Licence data US FDA:
Legal status
Routes of
Pharmacokinetic data
Bioavailability >70%
Protein binding 35%
Metabolism Hepatic
Biological half-life 1-2 hours
Excretion Renal
CAS Registry Number  Y
ATC code A02
PubChem CID:
DrugBank  Y
ChemSpider  Y
Chemical data
Formula C12H21N5O2S2
Molecular mass 331.46 g/mol

Nizatidine is a histamine H2-receptor antagonist that inhibits stomach acid production, and is commonly used in the treatment of peptic ulcer disease and gastroesophageal reflux disease. It was developed by Eli Lilly and is marketed under the brand names Tazac and Axid.


  • Clinical use 1
  • Adverse effects 2
  • History and development 3
  • See also 4
  • References 5
  • External links 6

Clinical use

Nizatidine is used to treat duodenal ulcers, gastric ulcers, and gastroesophageal reflux disease (GERD), and to prevent stress ulcers.[1]

Adverse effects

Side effects are uncommon, usually minor, and include diarrhea, constipation, fatigue, drowsiness, headache, and muscle aches.[1]

History and development

Nizatidine was developed by Eli Lilly, and was first marketed in 1987. It is considered to be equipotent with ranitidine and differs by the substitution of a thiazole ring in place of the furan ring in ranitidine. In September 2000, Eli Lilly announced they would sell the sales and marketing rights for Axid to Reliant Pharmaceuticals.[2] Subsequently, Reliant developed the oral solution of Axid, marketing this in 2004, after gaining approval from the U.S. Food and Drug Administration (FDA).[3] However, a year later, they sold rights of the Axid Oral Solution (including the issued patent[4] protecting the product) to Braintree Laboratories.[5]

Nizatidine proved to be the last new histamine H2-receptor antagonist introduced prior to the advent of proton pump inhibitors.

See also

  • Famotidine, Pepcid AC, Pepcidine: another popular H2-receptor antagonist


  1. ^ a b c "Nizatidine". Retrieved 2015-10-11. 
  2. ^ [4]
  3. ^ [5]
  4. ^ "United States Patent: 6930119". Retrieved 2015-10-11. 
  5. ^ [6]

External links

  • Axid @ FDA
  • Axid Oral Solution
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from World eBook Library are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.